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Pediatric hematopoietic stem cell transplantation (HSCT) offers cure for high-risk malignancies and other
conditions, but carries a risk of complications. Parental outlook regarding their child’s transplantation
course and future health has been largely unexplored. This report presents the Parent Outlook Scale, de-
scribes its properties, and examines the outlook of parents embarking on their child’s transplantation
course and the associated variables. Parents of children scheduled to undergo HSCT (n ¼ 363) at 8 US
transplantation centers completed the Parent Outlook Scale, comprising 4 items assessing frequency of the
parent’s thoughts about the potential difﬁculty of the child’s transplantation (Transplant Difﬁcult subscale)
and worsened health (Health Worse subscale). Item responses were rated on a 5-point Likert scale (ranging
from “none” to “all of the time”) and, along with scale/subscale scores, transformed to 100-point scales,
with higher scores connoting greater thought frequency. Psychometrics were explored. Multivariable
models identiﬁed personal and clinical characteristics associated with scale and subscale scores. The Parent
Outlook Scale (a ¼ 0.75) and subscales were found to have sound psychometric properties. Factor loading
supported the single scale with 2 subscales representing distinct aspects of overall outlook. Mean scores
(Parent Outlook, 52.5  21.7; Transplant Difﬁcult, 64.4  25.6; Health Worse, 40.7  25.7) revealed vari-
ability within and across scale/subscales. Signiﬁcantly different mean subscale scores (P < .001) indicated
more frequent Transplant Difﬁcult thoughts than Health Worse thoughts. Clinical factors (solid tumor
diagnosis and unrelated donor transplant) and a parent factor (worse emotional functioning) were asso-
ciated with higher scale and subscale scores. Our ﬁndings show that the outlook of parents embarking on
their child’s HSCT course is varied and not solely a product of clinical factors readily apparent to clinicians.art in poster form at the International
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spectives and concerns before and during the course of HSCT.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION The need to improve our understanding of HSCT patient/
Hematopoietic stem cell transplantation (HSCT) affords
potential cure, often the sole possibility of cure, for children
with high-risk malignancies and other life-threatening con-
ditions [1-7]. However, it is intensive therapy posing a risk
for serious complications and lasting health sequelae that
impair functioning and well-being [8-13]. Parents therefore
embark on their child’s transplantation experience holding
both hope for their child’s recovery and fear of what the
future may bring [14].
Given the risks of HSCT and the serious underlying
diagnosis, health outcomes (eg, future health, survival)
are difﬁcult to accurately predict for a given child. Parents’
uncertainty and fears are heighted by the unfamiliar and
complex nature of HSCT [15]. In this context of high appre-
hension and unknown outcomes, how parents regard the
transplantation course and their child’s potential health
outcomes (ie, parent outlook) once they have committed to
HSCT is largely unknown.
An understanding of parent outlook provides an impor-
tant window into a parent’s preparation, perspectives, and
concerns regarding HSCT. Knowledge of parent outlook
positions clinicians to effectively support and communicate
with parents and, in turn, maximize the physical and
psychological health of children and parents. On the other
hand, assumptions or misperceptions about parent per-
spectives can impede optimal communication, decision
making, and preparation, and in fact contribute to patient/
parent distress [16,17].
Despite its importance, parent outlook has been largely
unexplored. In 2 qualitative studies of parents of children
undergoing HSCT, parents expressed their fear of the perils
of HSCT and described being either incapable or unwilling
to think about the situation or their child’s potential outcome
[14,18]. Some actively pushed the possibility that their
child might die out of their minds, whereas others simply
denied this possibility [14]. Additional research building on
these 2 relatively small studies is needed to deepen our
understanding of parent outlook. It is possible that HSCT
parents alternatively have persistent, continuous thoughts
(ie, rumination) about the danger that might lie ahead
[19], or they may, like other parents of children with cancer,
contemplate the future but either not dwell on it or actively
focus on positive outcomes or aspects of the situation
[15,20-24]. Clearly, parents might think about the upcoming
transplantation and their child’s future health in a variety of
ways.
The factors shaping the outlook of parents as they embark
on their child’s HSCT course are also poorly understood.
Studies suggest that parents’ contemplation of HSCT risks
and adverse outcomes may be inﬂuenced by their sense of
culpability for a potentially poor outcome, their lack of
control over the situation, and the absence of an alternative
treatment offering cure [18,25]. The highly cure-oriented
setting of HSCT and the social desirability of positive
thinking [26,27] also may promote thoughts focused on
positive outcomes.parent perspectives and their preparation for potential out-
comes throughout the course of HSCT is increasingly evident
[14,16,28-30]. The Parent Outlook Scale was developed to
assess parent outlook. In the present study, we evaluated the
properties of this instrument, as well as the association of
variables with parent outlook asmeasured by this scale using
data from2 of the largest health-related quality of life (HRQL)
studies conducted in this population to date.
MATERIALS AND METHODS
Participants
Participants (n ¼ 363) were drawn from 2 prospective, multicenter
studies evaluating child and parent HRQL over the ﬁrst year after the
child’s HSCT (Figure 1). This analysis focuses on parent-reported outcomes
collected just before their child embarked on the course of HSCT. The
2 studies, Journeys to Recovery (JTR) and Hematopoietic Stem Cell Trans-
planteComprehensive Health Enhancement Support System (HSCT-CHESS),
are described in detail elsewhere [31-36] and brieﬂy summarized here. The
2 studies enrolled childeparent dyads from 8 US transplantation centers and
together spanned 2003-2011. Eligible children were aged 5 to 18 years (JTR)
or 2 months to 18 years (HSCT-CHESS), were scheduled to undergo HSCT,
provided age-appropriate assent, and had an eligible parent who provided
consent to participate and informed permission for the child to participate.
Parent eligibility criteria included aworking knowledge of English (validated
studymeasureswere available in English only) andminimumage of 18 years.
If more than 1 parent was involved in the child’s care, they were asked to
select 1 for participation. The Institutional Review Boards of Tufts Medical
Center and all participating transplantation centers approved the studies.
Measures
The General Health Module of the Child Health Rating Inventories
(CHRIs-General) assesses general health and HRQL (physical, emotional, and
role functioning, as well as global HRQL) in chronically ill children in the
preceding week via child and/or parent-proxy versions that have been
validated in the pediatric HSCT population [33,37-39]. The parent version of
the CHRIs-General contains a summary item regarding the child’s general
health (rated on a 5-point Likert scale ranging from “poor” to “excellent,”
converted to a 100-point scale) and items assessing parents’ own HRQL
(physical, emotional, and role functioning and global HRQL).
The version administered before HSCT also contains parent outlook
items reﬂecting frequency of the parent’s thoughts about the difﬁculty of the
impending transplantation for the child (“Transplant will be difﬁcult for my
child”) and parent (“Transplant will be difﬁcult for me”), worsening of their
child’s health (“My child’s future health will be worse than it is now”), and
child mortality (“My child might die”). Together the 4 items compose the
Parent Outlook Scale, with the 2 transplant difﬁcult and 2 worsened health
items forming the Transplant Difﬁcult and Health Worse subscales,
respectively.
The primary focus of the present analysis was on parents’ response to
the 4 outlook items and resultant Parent Outlook Scale and 2 subscale
scores. For each item, parents rated the frequency of their thoughts on a
5-point Likert scale, with response options of “1, none of the time”; “2, a
little of the time”; “3, some of the time”; “4, most of the time”; and “5, all of
the time.” Both item responses and computed mean scale and subscale
scores (range, 1-5) were converted to a 100-point scale (with higher values
representing greater frequency of thoughts) to facilitate interpretation of
univariate and multivariable analyses, described below.
Data Collection
Parents provided demographic information and completed the CHRIs-
General by paper and pencil either before or during the HSCT preparative
regimen. Detailed medical information, including the child’s diagnosis,
pretransplantation course, transplantation characteristics, and subsequent
vital status, was abstracted from the medical record by trained study staff at
each site and reviewed by the principal investigator (S.K.P.).
Ineligible
(n = 331)
Total number of 
patients
(n = 1079)
Screened for 
eligibility
(n = 962)
Eligible
(n = 631)
Consented 
(n = 389)
Not screened
(n = 117)
Declined participation 
(n = 242)
Baseline 
Assessment
Completed
(n = 363)
Baseline Assessment not completed
(n = 26)
Figure 1. Flow diagram of study participants. The study sample was derived from 2 studies: Journeys to Recovery, a longitudinal observational study, and
HSCT-Comprehensive Health Enhancement Support System, a randomized controlled study that evaluated the efﬁcacy of a web-based intervention providing
information and support resources for parents of children post-HSCT.
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Factor analysis with varimax rotation was used to explore scale prop-
erties, with factor loadings for items required to be0.4. We examined scree
plots to identify the number of factors with eigenvalues 1.00. We forced a
1- and 2-factor solution for the Parent Outlook Scale and the 2 subscales,
respectively. Pearson correlations between items were reported for the
subscales. Cronbach’s a was calculated to estimate the internal consistency
reliability of the Parent Outlook Scale. Theminimum acceptable criterion for
Cronbach’s a in exploratory scale development is 0.70, whereas for estab-
lished scales, Cronbach’s a should exceed 0.80 [40].
Descriptive statistics summarized child, parent, and clinical character-
istics and parent response frequencies. Associations among child, parent,
and clinical variables and the scale and subscale scores were tested with
univariate linear regression models. Variables with P  .10 on univariate
analysis were considered candidates for inclusion in multivariable linear
regression models and then eliminated by backward selection (retention
criterion P .10). Multivariable models controlled for potential confounders,
including transplantation center, study/study arm, and timing of baseline
assessment relative to the preparative regimen (ie, before versus during the
preparative regimen) [41]. Analyses were conducted using SAS version 9.4
(SAS Institute, Cary, NC).RESULTS
Study Sample
Data were available from 363 parents who completed
the CHRIs-General before transplantation (Figure 1). Table 1
presents characteristics of these parents and their children.
The mean CHRIs summary score for parent emotionalfunctioning was 49.6  19.3, indicating signiﬁcant impair-
ment [41].
Parent Outlook Scale and Subscales
Table 2 summarizes characteristics of the Parent Outlook
Scale, subscales, and individual items. Mean Parent Outlook
Scale, Transplant Difﬁcult, and Health Worse values indi-
cated 1 factor with an eigenvalue 1.00. For the 1-factor
solution, all 4 factor loadings were 0.58, indicating that
all items contributed substantially to the construct of parent
outlook. For the 2-factor solution, loadings were 0.67 and
0.89 for the Transplant Difﬁcult subscale and 0.77 and 0.65
for the HealthWorse subscale, supporting the idea that these
2 subscales represent distinct aspects of overall outlook.
Mean scores revealed variation within and across the
Parent Outlook Scale and subscales. Parents had more
frequent Transplant Difﬁcult thoughts than Health Worse
thoughts, as indicated by signiﬁcantly higher Transplant
Difﬁcult subscale scores than Health Worse subscale scores
(P < .001). The plots of percentages of parent responses to
individual outlook items shown in Figure 2 also demonstrate
that parents’ responses span the full spectrum of response
options. Most parents thought frequently about the difﬁculty
of HSCT for their child, with 87% having such thoughts
at least “some” or “all” of the time. More than one-half of
Table 1
Characteristics of Children and Parents
Characteristic Value
Children (n ¼ 363)
Age, yr, mean  SD 9.6  5.1
Female sex, n (%) 169 (47)
Months since diagnosis, median (IQR) 11 (5-37)
Diagnosis, n (%)
Nonmalignant condition 100 (27)
Hematologic malignancy 206 (57)
Solid tumor (peripheral or central nervous system) 57 (16)
Previous treatment unsuccessful, n (%)* 118 (32)
Transplant type, n (%)
Autologous 83 (23)
Allogeneic related donor 89 (24)
Allogeneic unrelated donor 192 (53)
Transplantation center, n (%)
Center A 4 (1)
Center B 28 (8)
Center C 29 (8)
Center D 39 (11)
Center E 52 (14)
Center F 57 (16)
Center G 62 (17)
Center H 92 (25)
Child general health (parent-reported), mean  SDy 52.0  28.5
Study/study arm, n (%)
JTR 165 (45)
HSCT-CHESS control arm 100 (28)
HSCT-CHESS intervention arm 98 (27)
Parents (n ¼ 363)
Age, yr, mean  SDz 38.7  7.5
Female sex, n (%) 301 (83)
Race/ethnicity, n (%)x
Nonwhite non-Hispanic 39 (11)
Hispanic 64 (18)
White 252 (71)
Postsecondary education, n (%) 251 (69)
Married/living with partner, n (%) 292 (80)
Emotional functioning, mean  SDk 49.6  19.3
SD indicates standard deviation; IQR, interquartile range; JTR, Journeys
to Recovery study; HSCT-CHESS, Hematopoietic Stem Cell Trans-
planteComprehensive Health Enhancement Support System study.
* Unsuccessful previous treatment deﬁned as previous disease relapse or
unplanned second HSCT.
y One parent did not report.
z Ten parents did not report.
x Eight unknown/missing.
k Emotional functioning scale score of the Child Health Rating Inventories
General Health Module.
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thoughts (“some” or “all” of the time). Interestingly, these
parents were no more likely than parents with infrequent
thoughts to have a child who died within 12 months (n ¼ 33
[17%] versus n ¼ 30 [18%]; P ¼ .80).Table 2
Characteristics of the Outlook Scale, Transplant Difﬁcult and Health Worse Subsca
N N Miss
Transplant Difﬁcult subscale* 363 0
Transplant will be difﬁcult for my child. 362 1
Transplant will be difﬁcult for me. 363 0
Health Worse subscale* 363 0
My child’s future health will be worse than it is now. 363 0
My child might die. 363 0
Parent Outlook Scale (a ¼ 0.75)* 363 0
CC indicates the Pearson correlation coefﬁcient for items within a subscale.
Parents rated the frequency of their thoughts on a 5-point Likert scale, with respo
time”; “4, most of the time”; and “5, all of the time.” Mean raw scale and subscale s
higher values representing greater frequency of thoughts).
* Higher scores reﬂect greater frequency of parent thoughts about the potential dVariables Associated with Parent Outlook Scale and
Subscale Scores
In univariate analyses, older parent and child age were
associated with lower scores (lower thought frequency), and
non-Hispanic white race was associated with higher scores
across the Parent Outlook Scale and the 2 subscales (Table 3);
however, these variables did not retain signiﬁcance in the
multivariate models. There were no signiﬁcant differences in
scores between mothers and fathers. Mean scores did range
widely across the 8 sites (Parent Outlook Scale, 41.7  24.2 to
60.5  22.5; Transplant Difﬁcult, 56.5  27.7 to 70.0  26.1;
Health Worse, 25.6  27.6 to 51.0  26.6). Such variation was
signiﬁcant (P > .001 for all).
Multivariable models of the Parent Outlook Scale and
subscale scores were largely similar. Unrelated donor allo-
geneic transplantation and worse parent emotional func-
tioning were signiﬁcantly associated with higher Parent
Outlook Scale and subscale scores. Parents of children with
a hematologic malignancy or nonmalignant condition had
better Parent Outlook Scale and subscale scores compared
with parents of children with a solid tumor. The change in
direction of effect (negative to positive) of HSCT type in
multivariate models adjusting for diagnosis is likely related
to the relationship between solid tumor diagnosis and
autologous HSCT; almost all (92%) children with a hemato-
logic malignancy or nonmalignant condition received an
allogeneic transplant, whereas all childrenwith a solid tumor
received an autologous transplant.
Differences between the multivariate models of the
Parent Outlook Scale and subscale scores were observed as
well. Whereas the worse parent-reported child general
health variable was associated with higher Parent Outlook
Scale and HealthWorse subscale scores, it had no association
with Transplant Difﬁcult subscale score. Another marker of
the child’s previous health, unsuccessful previous treatment,
also had no associationwith the Transplant Difﬁcult subscale
score.
DISCUSSION
In this paper, we have introduced the Parent Outlook
Scale and its subscales and reported scale and subscale
scores among parents of children embarking on HSCT and
variables associated with these scores. Demonstrated to be
psychometrically sound, based on observed factor structure
and Cronbach’s a, the Parent Outlook Scale and its subscales
permit unique insight into the outlook of parents embark-
ing on their child’s HSCT course with regard to the trans-
plantation and their child’s health outcomes. Variation in
frequency of parents’ outlook and thoughts, both withinles, and Individual Outlook Items
ing CC Mean SD Minimum Maximum
64.4 25.6 0 100
0.66 66.8 26.9 0 100
0.66 70.0 29.4 0 100
40.7 25.7 0 100
0.55 39.6 29 0 100
0.55 41.9 28.2 0 100
52.5 21.7 0 100
nse options of “1, none of the time”; “2, a little of the time”; “3, some of the
cores (range, 1-5) were computed and converted to a 100-point scale (with
ifﬁculty of the transplantation course or their child’s worsened future health.
Figure 2. Distribution of parent responses to outlook items based on frequency of thoughts. For all items, responses ranged from “none of the time” to “all of the
time.” At least one-half of all parents reported very frequent (“most” or “all of the time”) thoughts about the anticipated difﬁculty of transplantation for their child
(“Transplant will be difﬁcult for my child”) or themselves (“Transplant will be difﬁcult for me”). Far fewer reported frequent thoughts about adverse child health
outcomes (“My child’s future health will be worse than it is now” and “My child might die” items). n ¼ 363 for all except “transplant worse,” with n ¼ 362.
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notable.
Interestingly, more than one-half of parents reported very
infrequent (“a little” or “none of the time”) thoughts that
their child’s health might worsen or that their child might
die even as the child was about to begin intensive and risky
treatment. Because the vast majority of parents acknowl-
edged the potential difﬁculty of HSCT, incomplete awareness
of the rigors and risks of transplantation does not fully
explain this ﬁnding. Outlook may reﬂect to some degree a
coping strategy for managing fear and lack of control by
focusing on immediate challenges over which a parent may
feel a greater sense of control as opposed to distant and
frightening outcomes, such as deterioration of their child’s
health.
Parent outlook was signiﬁcantly associated with a variety
of factors, including clinical factors (eg, diagnosis, type of
transplant), parent’s perception of the child’s overall health,
and parent’s emotional functioning. These ﬁndings show
that parent outlook is a complex phenomenon, a product not
merely of clinical factors readily apparent to clinicians, but
also of parents’ perception of clinical circumstances and
previous experience and emotional functioning.
We observed signiﬁcant variation in Parent Outlook Scale
and subscale scores across the 8 study sites. This variation
may reﬂect clinical differences (eg, case mix), or different
center-speciﬁc practices (eg, communication during HSCT
consultation and consent, availability of psychosocial sup-
port) [42]. Of note, beyond the observed across-site differ-
ences, there is likely within-site variation, based on our
observed scale score standard deviations. This may be an
interesting topic for future research.
We found a worse outlook in parents of children with
a solid tumor compared with parents of children with a
hematologic malignancy or nonmalignant condition. Thisﬁnding was unanticipated, given that most pediatric solid
tumors are treated with autologous transplants, which tend
to have fewer transplantation-related complications [43].
This discrepancymay be a result of parents facing autologous
HSCT thinking beyond short-term transplantation-related
outcomes. Even after recovering from the acute effects of
transplantation, children with solid tumors remain at very
high risk for relapse and, ultimately, mortality. Viewing HSCT
through the lens of parents of children with a solid tumor,
one can see how they could have very frequent thoughts
about the difﬁcult road ahead and adverse child outcomes,
even if the procedure itself carries less risk.
Parents of children undergoing unrelated donor alloge-
neic HSCT also had more frequent thoughts about the
difﬁculty of HSCT and worsened child health. This likely
reﬂects the nature of this type of transplant, which carries a
higher likelihood of complications. In general, parents who
perceived their child to have better health had lower Parent
Outlook Scale and Health Worse subscale scores (ie, fewer
thoughts). Interestingly, however, they did not have lower
Transplant Difﬁcult subscale scores. The same is true for
previous experience of unsuccessful treatment. This may
again speak to the widespread view that HSCT will be difﬁ-
cult for their child (and themselves), irrespective of their
child’s health status or previous treatment experience.
We found that impaired parent emotional functioning
was strongly associated with worse parent outlook, consis-
tent with previous observations [16,19,44-51]. Such
emotional stress and poor adjustment has negative conse-
quences for the parent [47,52] and in turn, the child [53-56].
Ongoing psychosocial support to bolster parent emotional
functioning, coping, and adjustment to the stressors of HSCT
is an essential component of comprehensive transplantation
care. Ideally, these supportive interventions are initiated in
advance of HSCT, and continue through it and beyond. An
Table 3
Univariate and Multivariate Analyses of Parent Outlook Scale and Transplant Difﬁcult and Health Worse Subscale Scores
Characteristic Outlook Transplant Difﬁcult Health Worse
Univariate Multivariate* Univariate Multivariate Univariate Multivariate
Beta (SE)y P Beta (SE) P Beta (SE) P Beta (SE) P Beta (SE) P Beta (SE) P
Child
Age, yr 0.7 (0.2) <.01 0.8 (0.3) <.01 0.6 (0.3) .04
Female sex 0.7 (2.3) .74 1.7 (2.7) .52 0.2 (2.7) .95
Diagnosis
Solid tumor Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Hematologic
malignancy
7.6 (2.7) <.001 11.0 (4.5) .01 10.1 (3.4) <.01 13.5 (5.7) .02 5.1 (3.5) .15 8.6 (5.4) .09
Nonmalignancy 6.5 (3.2) .04 12.5 (4.9) .01 5.8 (3.9) .14 11.2 (6.3) .08 7.2 (4.0) .07 13.7 (5.9) .02
Months (log) since
diagnosis
1.2 (1.0) .23 1.3 (1.2) .27 1.0 (1.2) .38
Previous treatment
unsuccessful
3.3 (2.5) .18 0.49 (2.8) .86 6.0 (2.9) .04
HSCT type
Autologous Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Allogeneic related 7.0 (3.3) .03 4.6 (4.2) .32 6.9 (4.0) .08 5.0 (5.4) .38 6.9 (3.9) .07 4.4 (5.1) .39
Allogeneic unrelated 0.1 (2.6) .96 10.8 (4.0) .01 0.7 (3.2) .83 10.6 (5.1) .04 1.0 (3.1) .75 10.9 (4.8) .02
General health (parent
report)
0.2 (.04) <.001 0.1 (.04) .03 0.2 (.05) <.001 0.1 (.05) .15 0.2 (.04) <.001 0.1 (.04) .04
Parent
Age, yr 0.4 (0.2) .02 0.5 (0.2) .02 0.3 (0.19) .1
Female sex 1.4 (2.7) .61 0.3 (3.3) .92 2.4 (3.3) .45
White non-Hispanic 7.9 (2.5) <.01 4.9 (3.1) .11 10.8 (3.0) <.001
Postsecondary education 0.7 (2.5) .77 4.9 (2.9) .1 3.2 (3.0) .29
Married/living with
partner
2.2 (3.2) .49 0.6 (3.8) .87 3.6 (3.7) .33
Emotional functioning 0.6 (.06) <.001 0.5 (.05) <.001 0.5 (.07) <.001 0.5 (.07) <.001 0.6 (.06) <.001 0.5 (.06) <.001
HSCT indicates hematopoietic stem cell transplantation; SE, standard error; Ref, reference value.
Signiﬁcant P values are in bold type.
* Multivariable models were adjusted for transplantation center, study/study arm, and timing of baseline assessment relative to the start of the preparative
regimen.
y Higher score (positive estimate) reﬂects greater frequency of parent thoughts about the potential difﬁculty of the transplantation course or their child’s
worsened future health. The SEs presented are robust SEs.
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caring for these children before and after HSCT also must be
prepared to take on these issues, as well as personal and
system-level barriers to timely care [36].
These ﬁndings remind us of the potential pitfall of
presuming to know a parent’s outlook, because parents may
be thinking about adverse outcomes even when clinical
indicators are favorable. Clinicians focusing on the medical
complications of transplantation riskmaymistakenly believe
they share the parents’ outlook, resulting in misunder-
standing and empathic failure. To avoid this, clinicians can
and should create opportunities to explore with parents
their concerns throughout the HSCT trajectory, irrespective
of how the clinical course unfolds. High-quality physician
communication before HSCT reduces parent psychological
distress [16] and builds trust and a therapeutic alliance
with parents during HSCT [57]. Parents and patients ﬁnd that
opportunities to communicate with clinicians about the
transplantation course help them cope with transplantation
[14,46,58,59]. Such efforts may greatly beneﬁt parents and in
turn, their children.
This study has several strengths, including self-reported
data combined with concomitant detailed clinical data
from medical records review. Many patient-reported
outcome studies in pediatric oncology/HSCT, including the
few that have examined the parent experience, were con-
strained by single center design or limited sample diversity
(eg, constrained to one diagnostic group), limiting their
generalizability. The multicenter design and the relatively
diverse sample (30% Hispanic or nonwhite), particularly inlight of the study population [43,60,61], are other strengths
of this study. Finally, this study builds on previous studies
that have described parent fear, stress, or impaired psycho-
logical functioning during or after HSCT [16,19,44-51], and
illustrates speciﬁc parental thoughts and thought patterns
before their child’s transplantation, deepening our under-
standing of their lived experience.
We also acknowledge this study’s limitations. First, the
fact that the majority of respondents were female might be
considered a limitation. Although the proportion of fathers is
small (17%), the actual number of fathers (n¼ 62) surveyed is
considerable and at least commensurate with other pub-
lished studies in this population [46]. In addition, we found
no signiﬁcant differences between mothers’ and fathers’
Parent Outlook Scale and subscale scores. Our overall sample
size is robust and likely sufﬁcient to permit detection of a
signiﬁcant difference if it existed. That being said, differences
between mothers and fathers with regard to psychological
distress and coping before HSCT have been described, and
this issue warrants further study [16,48]. Second, the study
sample was drawn in part from an intervention study,
although the ﬁndings presented are from data collected
occurred before randomization. Nevertheless, we controlled
for study arm in the analyses and found no effect. For these
reasons, the intervention is unlikely to inﬂuence the results.
Given the cross-sectional nature of this analysis, the direc-
tionality of association between parent emotional func-
tioning and parent outlook is also unknown. Our ﬁndings
presented here are limited to the pre-HSCT period. How
parent outlook evolves over the course of transplantation
C.K. Ullrich et al. / Biol Blood Marrow Transplant 22 (2016) 104e111110and its relationship to personally and clinically meaningful
endpoints during this course must be further delineated.
Such analyses are underway.
Multiple questions about parent outlook remain. For
example, are parents thinking about speciﬁc transplantation
risks or complications, and if so, over what time frame?
What, if any, frequency of parent thoughts about the trans-
plantation course or child outcomes is most adaptive?
Finally, to what degree does parent outlook reﬂect a parent’s
prognostic estimate, if it does at all? The Parent Outlook Scale
and its subscales hold promise from a psychometric stand-
point, and may be useful in future studies addressing these
questions.Implications for Care
This study sheds light on the “inner world” of parents
embarking on HSCT for their child, focusing on their
thoughts about the difﬁculty of transplantation or their
child’s health worsening despite (or because of) HSCT.
It highlights the important roles of both transplantation cli-
nicians and primary oncologists (or other specialty pro-
viders) in supporting families before, during, and after HSCT.
Through conversations with their primary oncologist or
other specialty provider, many patients and families have
considered HSCT and even decided to pursue it before the
consultation/consent meeting with the HSCT team [62,63].
Primary oncologists/specialists may well have an awareness
of the parent’s baseline emotional functioning, and should
share such insight with the transplantation team by making
them aware of particular family perspectives, worries, and
hopes, as well as family strengths and vulnerabilities, to
ensure that adequate support is available.
Understanding parent outlook is a cornerstone of clear
and compassionate communication throughout the course
of HSCT, allowing mutual understanding of hopes, fears,
expectations, and goals of care. Further efforts to understand
and support dialogue about parent outlook can deepen
clinician and parent understanding and are vital to ensuring
a clear and shared purpose and optimal support for families
throughout the transplantation course.ACKNOWLEDGMENTS
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